Press Releases

• Fourth quarter total revenue of $18.9 million, up 12% year-over-year
• Q4 adjusted EBITDA⁽¹⁾ of $0.9 million, up 18% year-over-year, and our 24^th consecutive quarter of positive adjusted EBITDA. Full year adjusted EBITDA up 19% year-over-year
• Positive cash flows, with significant investments in our facilities to support future growth
• In Q1 2025 performed the first-ever injection in North America of Arthrosamid^® (2.5% iPAAG) at its Mississauga, Ontario clinic
• In Q1 2025 secured a new Credit Facility with National Bank to support growth initiatives

TORONTO, ONTARIO, March 27, 2025 – NeuPath Health Inc. (TSXV:NPTH), (“NeuPath” or the “Company”), owner and operator of a network of clinics delivering category-leading chronic pain treatment, today announced its financial and operating results for the three months and year ended December 31, 2024. All figures are in Canadian dollars, unless otherwise noted.

“We once again delivered strong organic growth while continuing to invest in our facilities,” said Joe Walewicz, NeuPath’s Chief Executive Officer. “These investments, new procedures such as the recently launched Arthrosamid, and our new Credit Facility will accelerate organic and inorganic growth to better serve patients, with more services, in more communities.”

Financial and Operational Highlights

• Total revenue was $18.9 million and $72.8 million for the three months and year ended December 31, 2024, up 12% versus the fourth quarter of 2023 and 10% for the year, delivering another record year of revenues;
• Adjusted EBITDA was $0.9 million and $3.8 million for the three months and year ended December 31, 2024, up 18% over the prior year fourth quarter and 19% year-over-year;
• For the year ended December 31, 2024, capacity utilization improved to 75%, up from 68% in the prior year;
• As at December 31, 2024, the Company had $2.9 million in cash and cash equivalents and long-term debt of $5.9 million, of which $2.2 million is interest-bearing;
• In Q1 2025 performed the first-ever injection of Arthrosamid (2.5% iPAAG) in North America at its Mississauga, Ontario clinic. Arthrosamid is a unique non-biodegradable hydrogel injection developed by Contura International A/S, a biotechnology company based in Denmark. Unlike traditional osteoarthritis injections, Arthrosamid integrates into the synovial tissue of the knee, helping to cushion the joint and reduce pain with a single dose; and
• In Q1 2025 announced a new $13.5 million Credit Facility with National Bank, including a Term Loan, a Revolving Facility and an Acquisition Line to support the continued growth of the business.

(1)      Non-International Financial Reporting Standard (“IFRS”) and Other Financial Measures defined by the Company below.

Total Revenue

Total revenue is comprised of clinic revenue and non-clinic revenue. Total revenue was $18.9 million for the three months ended December 31, 2024 compared to $16.8 million for the three months ended December 31, 2023. Total revenue was $72.8 million for the year ended December 31, 2024 compared to $66.1 million for the year ended December 31, 2023.

Clinic Revenue

Clinic revenue is generated through the provision of medical services to patients. Clinic revenue was $17.5 million for the three months ended December 31, 2024 compared to $15.3 million for the three months ended December

31, 2023. Clinic revenue was $67.3 million for the year ended December 31, 2024 compared to $61.0 million for the year ended December 31, 2023. The increase in clinic revenue for the year ended December 31, 2024 was primarily due to stronger revenues from fluoroscopy and increased patient volumes from existing medical clinics.

Non-clinic Revenue

Non-clinic revenue was $1.4 million for the three months ended December 31, 2024 compared to $1.5 million for the three months ended December 31, 2023. Non-clinic revenue was $5.5 million for the year ended December 31, 2024 compared to $5.1 million for the year ended December 31, 2023. Non-clinic revenue is earned from physician staffing allocation services where the Company provides physicians for provincial and federal correctional institutions across Canada, and from contract research services provided to pharmaceutical companies and clinical research organizations. This revenue fluctuates depending on the need for physicians in certain institutions and the timing and enrolment of clinical studies that the Company is working on.

Gross margin % was 19.2% for the three months ended December 31, 2024 and December 31, 2023. Gross margin

% was 19.0% for the year ended December 31, 2024 compared to 18.6% for the year ended December 31, 2023. The increase in gross margin was primarily driven by higher revenues from fluoroscopy and increased patient volumes at existing medical clinics compared to the year ended December 31, 2023. (see Non-IFRS Financial Measures – Gross Margin and Gross Margin %).

Adjusted EBITDA was $0.9 million and $3.8 million for the three months and year ended December 31, 2024 compared to $0.8 million and $3.2 million for the three months and year ended December 31, 2023.

Liquidity and Capital Resources

As at December 31, 2024, the Company’s net debt was $3.0 million, compared to $2.9 million as at December 31, 2023. The Company’s net debt as at December 31, 2024 consisted of $2.9 million of cash and cash equivalents and long-term debt of $5.9 million compared to $3.2 million of cash and cash equivalents and long-term debt of

$6.1 million as at December 31, 2023.

For more information see Note 12, Long-Term Debt in the Company’s Consolidated Financial Statements for the three months and year ended December 31, 2024 and 2023.

Non-IFRS Financial and Other Measures

The Company discloses non-IFRS measures (such as EBITDA, adjusted EBITDA, and gross margin) and non- IFRS ratios (such as gross margin %) that do not have standardized meanings prescribed by International Financial Reporting Standards (“IFRS”). The Company believes that shareholders, investment analysts and other readers find such measures helpful in understanding the Company’s financial performance. Non-IFRS financial measures and other measures do not have any standardized meaning prescribed by IFRS and may not have been calculated in the same way as similarly named financial measures presented by other reporting issuers and therefore unlikely to be comparable to similar measures presented by other companies. Furthermore, these non-IFRS measures and other measures should not be considered in isolation or as a substitute for measures of performance or cash flows as prepared in accordance with IFRS. These measures should be considered as supplemental in nature and not as a substitute for related financial information prepared in accordance with IFRS.

EBITDA and Adjusted EBITDA

EBITDA refers to net income (loss) determined in accordance with IFRS, before depreciation and amortization, net interest expense (income) and income tax expense (recovery). The Company defines adjusted EBITDA, as EBITDA, excluding stock-based compensation expense, restructuring costs, gain on derecognition of other obligations, fair value adjustments, transaction costs, impairment charges, gain on sale of building, government loans forgiveness, finance income and loss or gain on sale of property, plant and equipment. Management believes EBITDA and adjusted EBITDA are useful supplemental non-GAAP measures to determine the Company’s ability to generate cash available for operations, working capital, capital expenditures, debt repayments, interest expense and income taxes.

The following table provides a reconciliation of net and comprehensive loss to EBITDA and adjusted EBITDA:

Gross Margin and Gross Margin %

Management believes gross margin and gross margin % are important supplemental non-GAAP measures for evaluating operating performance and to allow for operating performance comparability from period-to-period. Gross margin is calculated as total revenue minus cost of medical services (”COMS”). Gross margin % is calculated as gross margin divided by total revenue.

The following table provides a reconciliation of total revenue to gross margin:

For further details on the results, please refer to NeuPath’s Management, Discussion and Analysis and Consolidated Financial Statements for the three months and year ended December 31, 2024, which are available on the Company’s website (www.neupath.com) and under the Company’s profile on SEDAR+ (www.sedarplus.ca).

About NeuPath

NeuPath operates a network of healthcare clinics and related businesses focused on improved access to care and outcomes for patients by leveraging best-in-class treatments and delivering patient-centered multidisciplinary care. We operate a network of medical clinics in Ontario and Alberta that provide comprehensive assessments and rehabilitation services to patients with chronic pain, musculoskeletal/back injuries, sports related injuries and concussions. In addition, NeuPath provides workplace health services and independent medical assessments to employers and disability insurers through a national network of healthcare providers, as well as contract research

services to pharmaceutical and biotechnology companies. NeuPath is focused on enabling each individual to live their best life. For additional information, please visit www.neupath.com.

Forward-Looking Statements

This news release contains forward-looking statements. All statements, other than statements of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future including, without limitation, the Company’s expectation of continued operational improvements in 2025 and the execution of the Company’s growth opportunities are forward-looking statements. These forward-looking statements reflect the current expectations or beliefs of the Company based on information currently available to the Company. Forward-looking statements are subject to a number of risks and uncertainties that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements, and even if such actual results are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on, the Company. Factors that could cause actual results or events to differ materially from current expectations included in this news release include, among other things, adverse market conditions, risks associated with obtaining and maintaining the necessary governmental permits and licenses related to the business of the Company, increasing competition in the market and other risks generally inherent in the chronic pain, sports medicine, concussion and workplace health services markets. A comprehensive discussion of these and other risks and uncertainties can be found in the Company’s annual information form dated March 26, 2025 filed on SEDAR+ under the Company’s profile at www.sedarplus.ca.

Any forward-looking statement speaks only as of the date on which it is made and, except as may be required by applicable securities laws, the Company disclaims any intent or obligation to update any forward-looking statement, whether as a result of new information, future events or results or otherwise. Although the Company believes that the assumptions underlying the forward-looking statements are reasonable, forward-looking statements are not guarantees of future performance and accordingly undue reliance should not be put on such statements due to their inherent uncertainty.

For more information, please contact:

Jeff Zygouras
Chief Financial Officer [email protected] (905) 858-1368

NEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS THE RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Arthrosamid can provide pain relief for knee osteoarthritis patients for up to four years after a single procedure NeuPath continues to accelerate growth as it rolls out Arthrosamid across its clinic network Empowers NeuPath healthcare physicians to deliver innovative, best-in-class treatment to Canadians

TORONTO, ONTARIO, March 6, 2025 – NeuPath Health Inc. (TSXV:NPTH), (“NeuPath” or the “Company”), owner and operator of a network of clinics delivering category-leading chronic pain treatment, today announced that it has performed the first-ever injection of Arthrosamid in North America at its Mississauga, Ontario clinic. Prior to Health Canada’s approval of Arthrosamid, patients would travel to Europe to access this innovative hydrogel that has been shown to provide up to four years of pain relief for knee osteoarthritis sufferers.[1]

“This is a major step forward in osteoarthritis options for Canadians,” said Joe Walewicz, NeuPath’s Chief Executive Officer. “It underscores our commitment to provide best chronic pain care to our patients as we scale up our clinic network and expand our services across Canada. We continue to seek out proven, innovative treatments that leverage our growing market presence and the skills of our healthcare professionals.”

Over four million Canadians live with osteoarthritis, with knee osteoarthritis being a leading cause of pain, mobility issues and reduced quality of life. The economic burden of arthritisin Canada was estimated to be $6.4 billion, representing almost one third of the total cost of musculoskeletal diseases.[2] Worldwide, osteoarthritis is a leading cause of disability in older adults.[3] Conventional non-surgical solutions like painkillers and corticosteroid injections provide only temporary relief. The addition of Arthrosamid enables the Company to reinforce its leadership in treatments for chronic pain as it expands its footprint across Canada.

About Arthrosamid

Arthrosamid (2.5% iPAAG) is a unique non-biodegradable hydrogel injection developed by Contura International A/S, a biotechnology company based in Denmark. Unlike traditional OA injections, Arthrosamid integrates into the synovial tissue of the knee, helping to cushion the joint and reduce pain with a single-dose. Conventional non-surgical solutions like painkillers and corticosteroid injections provide only temporary relief. Hydrogel-based injections have been administered more than 1.4 million times to patients worldwide.

About NeuPath

NeuPath operates a network of healthcare clinics and related businesses focused on improved access to care and outcomes for patients by leveraging best-in-class treatments and delivering patient-centered multidisciplinary care. We operate a network of medical clinics in Ontario and Alberta that provide comprehensive assessments and rehabilitation services to clients with chronic pain, musculoskeletal/back injuries, sports related injuries and concussions. In addition, NeuPath provides workplace health services and independent medical assessments to employers and disability insurers through a national network of healthcare providers, as well as contract research services to pharmaceutical and biotechnology companies. NeuPath is focused on enabling each individual to live their best life. For additional information, please visit www.neupath.com.

Forward-Looking Statements

This news release contains forward-looking statements. All statements, other than statements of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future including, without limitation, the Company’s expectation of rolling out the Arthrosamid procedure across its clinics in Canada are forward-looking statements. These forward-looking statements reflect the current expectations or beliefs of the Company based on information currently available to the Company. Forward-looking statements are subject to a number of risks and uncertainties that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements, and even if such actual results are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on, the Company. Factors that could cause actual results or events to differ materially from current expectations included in this news release include, among other things, adverse market conditions, risks associated with obtaining and maintaining the necessary governmental permits and licenses related to the business of the Company, increasing competition in the market and other risks generally inherent in the chronic pain, sports medicine, concussion and workplace health services markets. A comprehensive discussion of these and other risks and uncertainties can be found in the Company’s annual information form dated March 14, 2024 filed on SEDAR+ under the Company’s profile at www.sedarplus.ca.

Any forward-looking statement speaks only as of the date on which it is made and, except as may be required by applicable securities laws, the Company disclaims any intent or obligation to update any forward-looking statement, whether as a result of new information, future events or results or otherwise. Although the Company believes that the assumptions underlying the forward-looking statements are reasonable, forward-looking statements are not guarantees of future performance and accordingly undue reliance should not be put on such statements due to their inherent uncertainty.

For more information, please contact:

Jeff Zygouras
Chief Financial Officer
[email protected]
(905) 858-1368

NEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS THE RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

 [1] Bliddal, H., et al. (2024) A Prospective Study of Polyacrylamide Hydrogel Injection for Knee Osteoarthritis: Results From 4 Years After Treatment. Presented at EORS 2024, Aalborg and Orthopaedic Proceedings of the Bone & Joint Journal.
[2] Life with arthritis in Canada: a personal and public health challenge, Government of Canada: canada.ca/en/public-health/services/chronic-diseases/arthritis/life-arthritis-canada-a-personal-public-health-challenge.html.
[3] Hunter, David J et al. (2020) Osteoarthritis in 2020 and beyond: a Lancet Commission; The Lancet, Volume 396, Issue 10264, 1711 – 1712: thelancet.com/journals/lancet/article/PIIS0140-6736(20)32230-3/fulltext

TORONTO, ONTARIO, December 10, 2024 – NeuPath Health Inc. (TSXV:NPTH), (“NeuPath” or the “Company”), owner and operator of a network of clinics delivering category-leading chronic pain treatment, today announced the grant of stock options (“Options”) and restricted share units (“RSUs”). All figures are in Canadian dollars, unless otherwise noted.

 Issuance of Stock Options and Restricted Share Units

 On December 9, 2024, NeuPath granted 150,000 Options to non-executive directors of the Company at an exercise price of $0.19 per share, with an expiry date of December 9, 2031. The Options are subject to time-based vesting and will fully vest on December 9, 2025.

 In addition, on December 9, 2024, the Company granted 60,000 RSUs to the same non-executive directors of the Company and 350,000 RSUs to two executive officers of the Company. The RSUs are subject to time-based vesting in accordance with the policies of the TSX Venture Exchange. RSUs granted to non-executive directors will fully vest on December 9, 2025. RSUs granted to executive officers of the Company will vest annually on each anniversary date from the date of grant for 4 years. The terms of the RSUs granted are in accordance with the Company’s Amended and Restated Restricted Share Unit Plan.

About NeuPath

 NeuPath operates a network of healthcare clinics and related businesses focused on improved access to care and outcomes for patients by leveraging best-in-class treatments and delivering patient-centered multidisciplinary care. We operate a network of medical clinics in Ontario and Alberta that provide comprehensive assessments and rehabilitation services to clients with chronic pain, musculoskeletal/back injuries, sports related injuries and concussions. In addition, NeuPath provides workplace health services and independent medical assessments to employers and disability insurers through a national network of healthcare providers, as well as contract research services to pharmaceutical and biotechnology companies. NeuPath is focused on enabling each individual to live their best life. For additional information, please visit www.neupath.com.

 Forward-Looking Statements

 This news release contains forward-looking statements. All statements, other than statements of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future including, without limitation, the Company’s expectation of continued operational improvements in 2024 and the execution of the Company’s growth opportunities are forward-looking statements. These forward-looking statements reflect the current expectations or beliefs of the Company based on information currently available to the Company. Forward-looking statements are subject to a number of risks and uncertainties that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements, and even if such actual results are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on, the Company. Factors that could cause actual results or events to differ materially from current expectations included in this news release include, among other things, adverse market conditions, risks associated with obtaining and maintaining the necessary governmental permits and licenses related to the business of the Company, increasing competition in the market and other risks generally inherent in the chronic pain, sports medicine, concussion and workplace health services markets. A comprehensive discussion of these and other risks and uncertainties can be found in the Company’s annual information form dated March 14, 2024 filed on SEDAR+ under the Company’s profile at www.sedarplus.ca.

Any forward-looking statement speaks only as of the date on which it is made and, except as may be required by applicable securities laws, the Company disclaims any intent or obligation to update any forward-looking statement, whether as a result of new information, future events or results or otherwise. Although the Company believes that the assumptions underlying the forward-looking statements are reasonable, forward-looking statements are not guarantees of future performance and accordingly undue reliance should not be put on such statements due to their inherent uncertainty.

 For more information, please contact:

 Jeff Zygouras
Chief Financial Officer
[email protected]
(905) 858-1368

NEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS THE RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

TORONTO, ONTARIO, November 27, 2024 – NeuPath Health Inc. (TSXV:NPTH) (NeuPath or the “Company”) announced today that the TSX Venture Exchange (the “Exchange”) has accepted a notice filed by NeuPath of its intention to make a Normal Course Issuer Bid (“NCIB”) to be transacted through the facilities of the Exchange.

Pursuant to the NCIB, the Company may, during the 12-month period commencing November 27, 2024 and ending November 26, 2025 (or on such date that the Company completes its purchases or provides notice of termination), purchase up to 2,820,044 common shares (“Shares”) in total, being approximately 5% of the total number of Shares outstanding as at November 27, 2024 (being 56,400,893 Shares). The price which the Company will pay for any such Shares will be the prevailing market price at the time of acquisition. Also, in accordance with the policies of the Exchange, the Company may not purchase more than 2% of its issued and outstanding Shares during any 30-day period. The actual number of Shares which may be purchased pursuant to the NCIB and the timing of any such purchases, outside of restricted periods, will be determined by management of the Company.

Purchases under the NCIB will be made from time to time by Haywood Securities Inc. (the “Broker”) on behalf of the Company through the facilities of the Exchange or through a Canadian alternative trading system. The Company has entered into a pre-defined plan with the Broker to allow for the purchase of Shares under the NCIB at times when the Company ordinarily would not be permitted to purchase Shares due to its internal trading black-out periods, insider trading rules or regulatory restrictions. The plan provides a set of standard instructions to the Broker to make purchases at its sole discretion under the NCIB in accordance with the terms set out in the such plan, the rules of the Exchange and applicable securities laws. Decisions regarding any future repurchases will depend on certain factors, such as market conditions, share price and instructions set forth in the plan. The Company may elect to suspend or discontinue share repurchases at any time in accordance with the plan and applicable laws.

To the knowledge of the Company, no director, senior officer or other insider of the Company, or any of their associates, or any associates or affiliates of the Company currently intend to sell Shares under the NCIB. All Share purchases will be made on the open market through the facilities of the Exchange and will be purchased for cancellation. The funding for any purchase pursuant to the NCIB will be financed out of the working capital of the Company.

The board of directors (the “Board”) believes the underlying value of the Company may not be reflected in the current market price of its Shares. As a result, depending upon future price movements and other factors, the Board believes that the purchase of Shares may represent an attractive investment to the Company and in the best interests of the Company. Furthermore, the purchases are expected to benefit all persons who continue to hold Shares by increasing their equity interest in the Company if the repurchased Shares are cancelled.

About NeuPath Health Inc.

NeuPath operates a network of healthcare clinics and related businesses focused on improved access to care and outcomes for patients by leveraging best-in-class treatments and delivering patient-centered multidisciplinary care. We operate a network of medical clinics in Ontario and Alberta that provide comprehensive assessments and rehabilitation services to clients with chronic pain, musculoskeletal/back injuries, sports related injuries and concussions. In addition, NeuPath provides workplace health services and independent medical assessments to employers and disability insurers through a national network of healthcare providers, as well as contract research services to pharmaceutical and biotechnology companies. NeuPath is focused on enabling each individual to live their best life. For additional information, please visit www.neupath.com.

Forward Looking Information:

This news release contains forward-looking statements. All statements, other than statements of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future. Forward-looking information in this press release includes statements with respect to the anticipated benefits of the NCIB and the number of Shares that may be purchased under the NCIB. These forward-looking statements reflect the current expectations or beliefs of the Company based on information currently available to the Company. Forward-looking statements are subject to a number of risks and uncertainties that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements, and even if such actual results are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on, the Company. Factors that could cause actual results or events to differ materially from current expectations included in this news release include, among other things, adverse market conditions, risks associated with obtaining and maintaining the necessary governmental permits and licenses related to the business of the Company, increasing competition in the market and other risks generally inherent in the chronic pain, sports medicine, concussion and workplace health services markets. A comprehensive discussion of these and other risks and uncertainties can be found in the Company’s annual information form dated March 14, 2024 filed on SEDAR+ under the Company’s profile at www.sedarplus.ca.

Any forward-looking statement speaks only as of the date on which it is made and, except as may be required by applicable securities laws, the Company disclaims any intent or obligation to update any forward-looking statement, whether as a result of new information, future events or results or otherwise. Although the Company believes that the assumptions underlying the forward-looking statements are reasonable, forward-looking statements are not guarantees of future performance and accordingly undue reliance should not be put on such statements due to their inherent uncertainty.

For further information, please contact:

Jeff Zygouras
Chief Financial Officer
[email protected]
(905) 858-1368

NEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS THE RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

• Third quarter total revenue of $17.6 million, up 9% year-over-year
• Adjusted EBITDA⁽¹⁾ of $0.7 million, up 9% year-over-year, and our 23^rd consecutive quarter of positive adjusted EBITDA
• Positive cash flow, with net debt down 8% versus September 30, 2023, and with significant investments in our facilities to support future growth

TORONTO, ONTARIO, November 14, 2024 – NeuPath Health Inc. (TSXV:NPTH), (“NeuPath” or the “Company”), owner and operator of a network of clinics delivering category-leading chronic pain treatment, today announced its financial and operating results for the three and nine months ended September 30, 2024. All figures are in Canadian dollars, unless otherwise noted.

“Continued organic growth and a focus on operations is funding investments in our clinics, which will drive growth in coming years,” said Joe Walewicz, NeuPath’s Chief Executive Officer. “Additionally, our improving Balance Sheet is allowing us to evaluate new opportunities for organic and inorganic growth to better serve more patients, with more services, in more communities.”

Financial and Operational Highlights

• Total revenue was $17.6 million and $53.9 million for the three and nine months ended September 30, 2024, up 9% over the prior year three-month and nine-month periods;
• Adjusted EBITDA was $0.7 million and $2.9 million for the three and nine months ended September 30, 2024, up 9% over the prior year three-month period and up 20% over the prior year nine-month period;
• For the nine months ended September 30, 2024, capacity utilization improved to 74%, up from 67% for the nine months ended September 30, 2023; and
• As at September 30, 2024, the Company had $3.1 million in cash and cash equivalents and long-term debt of $6.0 million, of which $2.3 million is interest-bearing.
  

(1) Non-International Financial Reporting Standard (“IFRS”) and Other Financial Measures defined by the Company below.

• NeuPath to report Q3 2024 results on November 14^th before market open

TORONTO, ONTARIO, October 21, 2024 – NeuPath Health Inc. (TSXV:NPTH), (“NeuPath” or the “Company”), is pleased to invite investors and other interested parties to attend an upcoming interview with Market Radius Research.

 NeuPath’s Chief Executive Officer, Joe Walewicz intends to discuss NeuPath’s untapped opportunities for growth as it expands to serve more patients, with more procedures, in more locations across Canada and to discuss the operational improvements the Company has made thus far in 2024.

 The webinar will be a live, interactive online event where attendees are invited to ask the Company questions in real-time following the interview. An archived webcast will be made available for those who cannot join the event live on the day of the webinar.

 Event: Radius Research Pitch, Deep Dive and Q&A Webinar with NeuPath Health Inc. (NPTH)

Presentation Date & Time: Thursday, October 24, 2024 at 1:30 PM ET / 10:30 AM PT

Webcast Registration Link: https://us02web.zoom.us/webinar/register/8917291161031/WN_WgUunkABRkynqiXSK_zNWQ

 Market Radius Research gives individual investors access to in-depth CEO interviews with deep-dive institutional level discussion and Q&A. Market Radius is hosted by Martin Gagel, former top-ranked technology analyst. By registering for this webinar, you agree to receive email communications from Market Radius Capital, Inc. and from the presenting company (with an option to unsubscribe). Your email will not be further shared. Martin Gagel and Market Radius Capital, Inc. are not registered or licensed to provide investment advice and may own shares in mentioned companies and may be compensated for these services. Content is for information purposes only and is not advice or recommendations and may include incomplete or incorrect information. Investing entails a high degree of risk. This is a production of Market Radius Capital, Inc.

About NeuPath Health Inc.

NeuPath operates a network of healthcare clinics and related businesses focused on improved access to care and outcomes for patients by leveraging best-in-class treatments and delivering patient-centered multidisciplinary care. We operate a network of medical clinics in Ontario and Alberta that provide comprehensive assessments and rehabilitation services to clients with chronic pain, musculoskeletal/back injuries, sports related injuries and concussions. In addition, NeuPath provides workplace health services and independent medical assessments to employers and disability insurers through a national network of healthcare providers, as well as contract research services to pharmaceutical and biotechnology companies. NeuPath is focused on enabling each individual to live their best life. For additional information, please visit www.neupath.com.                                                                                                       

Forward Looking Information:

This news release contains forward-looking statements. All statements, other than statements of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future including, without limitation, the Company’s expectation to file its third quarter results for 2024 by November 14, 2024, the Company’s expectation of continued operational improvements in 2024 and the execution of the Company’s growth opportunities are forward-looking statements. These forward-looking statements reflect the current expectations or beliefs of the Company based on information currently available to the Company. Forward-looking statements are subject to a number of risks and uncertainties that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements, and even if such actual results are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on, the Company. Factors that could cause actual results or events to differ materially from current expectations included in this news release include, among other things, adverse market conditions, risks associated with obtaining and maintaining the necessary governmental permits and licenses related to the business of the Company, increasing competition in the market and other risks generally inherent in the chronic pain, sports medicine, concussion and workplace health services markets. A comprehensive discussion of these and other risks and uncertainties can be found in the Company’s annual information form dated March 14, 2024 filed on SEDAR+ under the Company’s profile at www.sedarplus.ca.

Any forward-looking statement speaks only as of the date on which it is made and, except as may be required by applicable securities laws, the Company disclaims any intent or obligation to update any forward-looking statement, whether as a result of new information, future events or results or otherwise. Although the Company believes that the assumptions underlying the forward-looking statements are reasonable, forward-looking statements are not guarantees of future performance and accordingly undue reliance should not be put on such statements due to their inherent uncertainty.

 For further information, please contact:

Jeff Zygouras
Chief Financial Officer
[email protected]
(905) 858-1368

NEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS THE RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

• Delivered record second quarter total revenue of $18.9 million, up 11% year-over-year
• Adjusted EBITDA⁽¹⁾ of $1.3 million, our 22^nd consecutive quarter of positive adjusted EBITDA
• Improved cash flows, with net debt down 37% versus June 30, 2023

TORONTO, ONTARIO, August 15, 2024 – NeuPath Health Inc. (TSXV:NPTH), (“NeuPath” or the “Company”), owner and operator of a network of clinics delivering category-leading chronic pain treatment, today announced its financial and operating results for the three and six months ended June 30, 2024. All figures are in Canadian dollars, unless otherwise noted.

“The focus on our core clinics business over the past two years is delivering improved financial results, a reduced debt burden, and improved facilities,” said Joe Walewicz, NeuPath’s Chief Executive Officer. “In the next few quarters, we will continue to invest in our facilities to better serve our patients in the community.”

Financial and Operational Highlights

• Record total revenue of $18.9 million and $36.4 million for the three and six months ended June 30, 2024, up 11% and 10% year-over-year, respectively;
• Adjusted EBITDA was $1.3 million and $2.2 million for the three and six months ended June 30, 2024, up 30% and 22% year-over-year, respectively;
• For the six months ended June 30, 2024, capacity utilization improved to 75%, up from 68% for the six months ended June 30, 2023; and
• As at June 30, 2024, the Company had $2.9 million in cash and cash equivalents and long-term debt of $6.0 million, of which $2.3 million is interest-bearing.

TORONTO, ONTARIO, June 13, 2024 – NeuPath Health Inc. (TSXV:NPTH), (“NeuPath” or the “Company”), owner and operator of a network of clinics delivering category-leading chronic pain treatment, today announced the voting results from its Annual General and Special Meeting of Shareholders (the “Meeting”) held on June 12, 2024. All figures are in Canadian dollars, unless otherwise noted.

The results of the director elections were as follows:

The shareholders of the Company also voted: (i) to reappoint Ernst & Young LLP, Chartered Professional Accountants, Licensed Public Accountants, as auditors of the Company for the ensuing year, and (ii) to approve the Company’s amended and restated stock option plan in the form attached as Schedule “A” to the management information circular dated April 23, 2024 prepared in connection with the Meeting.

About NeuPath

NeuPath operates a network of healthcare clinics and related businesses focused on improved access to care and outcomes for patients by leveraging best-in-class treatments and delivering patient-centered multidisciplinary care. We operate a network of medical clinics in Ontario and Alberta that provide comprehensive assessments and rehabilitation services to clients with chronic pain, musculoskeletal/back injuries, sports related injuries and concussions. In addition, NeuPath provides workplace health services and independent medical assessments to employers and disability insurers through a national network of healthcare providers, as well as contract research services to pharmaceutical and biotechnology companies. NeuPath is focused on enabling each individual to live their best life. For additional information, please visit www.neupath.com.